Marker Therapeutics Stock Forecast, Price & News

Marker Therapeutics (NASDAQ:MRKR) Frequently Asked Questions

Is Marker Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marker Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Marker Therapeutics stock.
View analyst ratings for Marker Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Marker Therapeutics?

Wall Street analysts have given Marker Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Marker Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Marker Therapeutics' next earnings date?

Marker Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Marker Therapeutics.

How were Marker Therapeutics' earnings last quarter?

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01.
View Marker Therapeutics' earnings history.

How has Marker Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Marker Therapeutics' stock was trading at $1.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRKR stock has decreased by 10.1% and is now trading at $1.78.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MRKR?

3 analysts have issued 12-month target prices for Marker Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they expect Marker Therapeutics' stock price to reach $6.67 in the next year. This suggests a possible upside of 274.5% from the stock's current price.
View analysts' price targets for Marker Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Marker Therapeutics' key executives?

Marker Therapeutics' management team includes the following people:

• Peter L. Hoang, President, Chief Executive Officer & Director
• Anthony H. Kim, Chief Financial Officer
• Ann M. Leen, Chief Scientific Officer
• Mythili Koneru, Chief Medical Officer
• Gerald Garrett, Vice President-Clinical Operations

Who are some of Marker Therapeutics' key competitors?

Some companies that are related to Marker Therapeutics include Pharvaris (PHVS), Nabriva Therapeutics (NBRV), Calliditas Therapeutics AB (publ) (CALT), Chinook Therapeutics (KDNY), Chimerix (CMRX), Verastem (VSTM), Mirum Pharmaceuticals (MIRM), PLx Pharma (PLXP), Inventiva (IVA), Clovis Oncology (CLVS), VistaGen Therapeutics (VTGN), Epizyme (EPZM), Greenwich LifeSciences (GLSI), Avadel Pharmaceuticals (AVDL) and Intercept Pharmaceuticals (ICPT).
View all of MRKR's competitors.

What other stocks do shareholders of Marker Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS).

What is Marker Therapeutics' stock symbol?

Marker Therapeutics trades on the NASDAQ under the ticker symbol "MRKR."

Who are Marker Therapeutics' major shareholders?

Marker Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.39%), Millennium Management LLC (1.64%), Victory Capital Management Inc. (1.16%), Kennedy Capital Management Inc. (0.72%), Geode Capital Management LLC (0.69%) and Renaissance Technologies LLC (0.48%). Company insiders that own Marker Therapeutics stock include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker and Peter L Hoang.
View institutional ownership trends for Marker Therapeutics.

Which major investors are selling Marker Therapeutics stock?

MRKR stock was sold by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., State Street Corp, Northern Trust Corp, Citadel Advisors LLC, Susquehanna International Group LLP, Victory Capital Management Inc., Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Marker Therapeutics or view top insider-selling stocks.

Which major investors are buying Marker Therapeutics stock?

MRKR stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace LLP, AR Asset Management Inc., Vanguard Group Inc., Ergoteles LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Marker Therapeutics stock in the last two years include Frederick Gerald Wasserman, John Robert Wilson, Juan Vera, Paul Edward Walker, and Peter L Hoang.
View insider buying and selling activity for Marker Therapeutics or or view top insider-buying stocks.

How do I buy shares of Marker Therapeutics?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marker Therapeutics' stock price today?

One share of MRKR stock can currently be purchased for approximately $1.78.

How much money does Marker Therapeutics make?

Marker Therapeutics has a market capitalization of $147.88 million and generates $470,000.00 in revenue each year. The company earns $-28,710,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How many employees does Marker Therapeutics have?

Marker Therapeutics employs 44 workers across the globe.

What is Marker Therapeutics' official website?

The official website for Marker Therapeutics is www.markertherapeutics.com.

Where are Marker Therapeutics' headquarters?

Marker Therapeutics is headquartered at 3200 Southwest Freeway Suite 2240, Houston TX, 77027.

How can I contact Marker Therapeutics?

Marker Therapeutics' mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at (713) 400-6400 or via email at [email protected].